Corporate
Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, welcomes today’s decision of the
Pharmaceuticals
with passion
Corporate
GSK and Alfasigma announce agreement on worldwide rights for linerixibat
GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).
Corporate
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide license to the parenteral formulation of adibelivir (formerly IM 250) for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life threatening condition.
Therapeutic areas
Gastroenterology
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)
Vascular
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions
Rheumatology
We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis
Metabolic
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles
Nutraceuticals & Medical foods
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue
CSR
Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.